Parametric modeling of under-5 children survival among 30 African countries: Lognormal accelerated failure time gamma shared frailty model. by Bikis Liyew, Kemal Tesfa, Kassaye Demeke Altaye, Abeje Diress Gelaw, Alemu Teshale Bicha, Ayanaw Guade Mamo, Kassaw Chekole Adane

“…In this study, children born in Western Africa; children born in Eastern Africa; children born to mothers aged 15-19 years; maternal educational status; maternal decision autonomy; being female; place of delivery; number of ANC visits; children born among mothers who delivered by Cesarean section; mothers who have multiple birth outcome; children who were second birth order; and third birth order and third birth order; children who were small in size at birth; children who were born from a community with a low women education; having poor wealth index; respondents working; mothers delivered at the age between 20-35 were significant predictors of survival time to event of under-five children in Africa.<h4>Conclusion</h4>This study found that the overall under-five mortality rates remain high across Africa. …”
Get full text

Mid-term outcomes of moderate-severe cystocele repairing with autologous fascia lata harvested through a small incision by Bo Yu, Junfang Yang, Qingyang Nie, Kun Zhang, Jinsong Han, Yiting Wang

“…One patient developed thromboembolic event. Harvest site: 2.86% (1/35) developed a non-bothersome thigh bulge, 17.14% (6/35) noted an impact on wound appearance, and 8.57% (3/35) reported mild paresthesia. …”
Get full text

Quantifying uncertainty in anthropogenic causes of injury and mortality for an endangered baleen whale by Daniel W. Linden, Jeffrey A. Hostetler, Richard M. Pace III, Lance P. Garrison, Amy R. Knowlton, Véronique Lesage, Rob Williams, Michael C. Runge

“…The model results also suggested that despite vessel strikes causing a lower average rate of severe injuries, the higher mortality rate conditional on injury results in significant total mortality risk, particularly for females resting from a recent calving event. Large uncertainty in the estimation of carcass recovery rate for vessel strike deaths permeated into the apportionment of mortality causes. …”
Get full text

Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports by Alessandro Ceschi, Roberta Noseda, Raffaela Bertoli, Laura Müller

“…Background Immune checkpoint inhibitor (ICI) use in clinical practice has unravelled a spectrum of immune-related adverse events (irAEs) due to immune system hyper-activation. …”
Get full text

Management of volume load for patients undergoing hemodialysis via WeChat and home monitoring in China: a protocol for a cluster-randomized trial by Xiaocui Wang, Bonan Yan, Shipeng Zhang, Yuanke Zhou, Qinxiu Zhang, Xueying Li

“…This method may also reduce adverse events and improve patient outcomes. Method The study will be conducted at the Hemodialysis Center of the Hospital of Chengdu University of Traditional Chinese Medicine, recruiting 135 participants. …”
Get full text

Sex Disparity in Characteristics, Management, and In-Hospital Outcomes of Patients with ST-Segment Elevated Myocardial Infarction: Insights from Henan STEMI Registry by Shan Wang, You Zhang, Qianqian Cheng, Datun Qi, Xianpei Wang, Zhongyu Zhu, Muwei Li, Junhui Zhang, Dayi Hu, Chuanyu Gao, On behalf of Henan STEMI registry study group

“…We analyzed 5063 STEMI patients prospectively enrolled from 66 hospitals during 2016–2018 and compared sex differences in mortality, death, or treatment withdrawal and main adverse cardiovascular and cerebrovascular events (MACCE) using the generalized linear mixed model, following sequential adjustment for covariates. …”
Get full text

Use of isavuconazole in mucormycosis: a systematic review by Shobha Sanjeewani Gunathilaka, Reshani Kaumada Keragala, Kasun Madhumal Gunathilaka, Sujanthi Wickramage, Sachithra Ravindi Bandara, Indika Sanjeewa Senevirathne, Asela Sampath Jayaweera

“…Short conclusion The use of isavuconazole in combination therapies during the acute phase via intravenous administration alongside LAmB or other triazoles, followed by long-term monotherapy via the oral route, has yielded promising recovery rates. Adverse events associated with the use of isavuconazole are infrequently reported.…”
Get full text

Gender Differences Are a Leading Factor in 5-Year Survival of Patients with Idiopathic Pulmonary Fibrosis over Antifibrotic Therapy Reduction by Pasquale Tondo, Giulia Scioscia, Cosimo C. De Pace, Fabiola Murgolo, Federica Maci, Giulia M. Stella, Dalila Pescatore, Maria Pia Foschino Barbaro, Donato Lacedonia

“…Data on comorbidities, smoking, antifibrotic therapy type, dosage adjustments, and adverse events were collected. We used Kaplan–Meier survival curves and logistic regression to assess gender-related differences in outcomes. …”
Get full text

Telaprevir: options of application in separate patient groups by M. V. Mayevskaya, I. N. Tikhonov, V. T. Ivashkin

“…Known risk factors of death or severe adverse events are level of platelets under 100 Gi/L, serum albumin level less than 3,5 g/dl, and HVPG ≥10 mm Hg. …”
Get full text

Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single... by Yingyi Li, Yuqin Cao, Xipeng Wang, Chengqiang Li, Liqin Zhao, Hecheng Li

“…Secondary outcomes of the study include the objective response rate (ORR), R0 resection rate, major pathological response (MPR) rate, and pCR rate in combined positive score(CPS) ≥ 5 and MSI-H populations, event-free survival (EFS), and overall survival (OS). …”
Get full text

Efficiency and safety of HAIC combined with lenvatinib and tislelizumab for advanced hepatocellular carcinoma with high tumor burden: a multicenter propensity score matching analys... by Zhonghua Zhao, Xiongying Jiang, Shiping Wen, Yanzhang Hao

“…Our primary endpoint was overall survival (OS); and secondary endpoints included adverse events (AEs), progression-free survival (PFS), disease control rate (DCR) and objective response rate (ORR) according to RECIST 1.1 criteria, respectively.ResultsAfter eligibility reviewed, total 162 patients treated with lenvatinib and tislelizumab were enrolled: 63 patients with HAIC (HTP group), and the remaining 99 patients without HAIC (TP group). …”
Get full text

Farmers’ Perception of the Impacts of Climate Variability and Change on Food Security in Rubanda District, South Western Uganda by Willbroad, Byamukama, Bello N.J, Omoniyi T.E

“…Climate variability and change factors have the potential for climatic stress on food security according to the observed agricultural production decline and farmers are seasonally faced with problems of food deficits due to unpredicted extreme weather events. The study established that policies, improved access to climate forecasting and dissemination and accessible extension service should be directed toward interventions to improve agriculture productivity by addressing issues concerning aspects of climate variability and change that constantly affect the dimensions of food security.…”
Get full text

Variability of plankton communities in relation to the lunar cycle in oceanic waters by Santiago Hernández-León, M. Loreto Torreblanca, M. Loreto Torreblanca, Inma Herrera, Inma Herrera, Laia Armengol, Gara Franchy, Alejandro Ariza, Juan Carlos Garijo, María Couret

“…Chlorophyll a, primary production, and zooplankton biomass were low, showing a rather weak late winter bloom event due to the high temperature and stratification observed. …”
Get full text

Linking evidence for targeted blood biomarkers in post-stroke cognitive impairment and dementia by Jinny Hong, Katherine Mun, Katherine Mun, Kyle C. Kern, Kyle C. Kern, Marissa Thirion, Jason D. Hinman, Jason D. Hinman

“…Critical to the assessment of prior studies includes defining the sample collection period and cognitive assessment period of prior studies to assess the temporal pattern of biomarker levels in relation to an incident stroke event. In addition to this comprehensive review, we performed a protein-protein network analysis of the putative blood biomarkers for PSCID and (surprisingly) find they exist in a highly connected protein-protein interaction network centered on inflammatory and neurodegenerative biomarkers suggesting shared biology underlies the pathogenesis of PSCID. …”
Get full text

Cresp®: transforming the landscape of chemotherapy-induced anemia - a comprehensive retrospective real-world analysis in 523 Indian patients by MV Chandrakanth, Vivek Agarwala, Pranav Sopory, Himadri Nayak, Purvish M. Parikh, Minakshi Roy, Rajib De, Pradeep Narayan, Anjuli Tuladhar Barai, Kaustav Mandal, Moinak Basu, Subhabrata Kumar, Rajdeep Singh Uppal, Syed Mujtaba Hussain Naqvi, Rohit Desai

“…The study measured the change in hemoglobin levels after DA administration as the primary outcome, with secondary outcomes including impact on blood transfusion dependence, changes in anemia-related symptoms, and occurrence of adverse events.ResultsA total of 523 patients, with a median age of 55, were included in the study. …”
Get full text

Accelerated symptom improvement in Parkinson’s disease via remote internet-based optimization of deep brain stimulation therapy: a randomized controlled multicenter trial by Alireza Gharabaghi, Sergiu Groppa, Marta Navas-Garcia, Alfons Schnitzler, Laura Muñoz-Delgado, Vicky L. Marshall, Jessica Karl, Lin Zhang, Ramiro Alvarez, Mary S. Feldman, Michael J. Soileau, Lan Luo, S. Elizabeth Zauber, Benjamin L. Walter, Chengyuan Wu, Hong Lei, Damian M. Herz, Ming-Hua Chung, Yagna Pathak, Bram Blomme, Binith Cheeran, Corneliu Luca, Daniel Weiss

“…None of the reported adverse events are related to RIBA. Conclusions This study demonstrates safety and efficacy of internet-based adjustment of DBS therapy, while providing clinical benefit earlier than in-clinic optimization of stimulation parameters by increasing patient access to therapy adjustment.…”
Get full text

Acute exacerbations in patients with progressive pulmonary fibrosis by Michael Kreuter, Elizabeth A. Belloli, Elisabeth Bendstrup, Stefania Cerri, Kevin R. Flaherty, Shane Shapera, Jin Woo Song, Heiko Mueller, Klaus B. Rohr, Yasuhiro Kondoh, on behalf of the INBUILD trial investigators, S. Quadrelli, M. Otaola, M.A. Bergna, P. Elias, G. Arce, A. Cazaux, J. Guiot, B. Bondue, C. Dahlqvist, L. Homik, S. Shapera, A. Cantin, M. Kolb, M. Salinas Fénero, R. Maturana Rozas, A. Silva Orellana, Z. Xu, Q. Luo, J. Kang, H. Cai, S. Marchand-Adam, E. Bergot, A. Gamez-Dubuis, F. Riviere, R. Kessler, H. Nunes, C. Marquette, L. Wemeau, S. Jouneau, F. Lebargy, B. Crestani, V. Cottin, M. Reynaud-Gaubert, S. Blaas, F. Bonella, W. Randerath, J. Hetzel, D. Koschel, M. Kreuter, A. Prasse, D. Skowasch, S. Stieglitz, R. Refini, S. Cerri, A. Pesci, S. Tomassetti, C. Vancheri, F. Varone, N. Sakamoto, S. Abe, H. Hayashi, T. Saito, T. Suda, H. Kitamura, M. Okamoto, Y. Kondoh, S. Makino, T. Takeuchi, Y. Yamada, C. Kono, Y. Inoue, H. Sugiura, K. Kishi, H. Takaya, H. Yamauchi, K. Ichikado, K. Tomii, H. Takahashi, S. Izumi, T. Kawamura, Y. Nishioka, Y. Miyazaki, J.W. Song, J.S. Park, Y. Kim, E. Jassem, J. Kus, W. Piotrowski, A. Barczyk, D. Ziora, E. Bazdyrev, S. Moiseev, S. Avdeev, M. Ilkovich, V. Yakusevich, C. Valenzuela, O. Acosta, M. Martínez, L. Gómez, M. Molina-Molina, D.M. Castillo Villegas, M. Aburto, J.A. Rodríguez Portal, A. Villar, A. León Jiménez, J. Sauleda, M. Arias, P. Beirne, H. Stone, B. Hope-Gill, N. Hirani, N. Chaudhuri, A. Gifford, L. Jones, L. Morrison, D. Antin-Ozerkis, N. Bhatt, T. Kulkarni, T. Moua, N. Ettinger, L. Pitts, S. Veeraraghavan, M. Padilla, E.R. Fernández Pérez, G. Giessel, M. Strek, S. Danoff, J. Burk, M. Rossman, N. Patel, E. Belloli, D. Hotchkin, S. Weigt, M.B. Scholand, R. Kaner, B. Sigal, Z. Safdar, L. Tolle, R. Martinez, M. Glassberg, R. Hallowell, J. Golden, M. Schwartz, E. Britt, L. Morrow, Y. Mageto, K. Buch, S. Chaaban, H. Poonyagariyagorn, D. Dilling, O. Shlobin, K. Thavarajah, A. Nambiar, I. Rosas, R. Bascom, J. Oldham, S. Schmidt, J. Dematte D'Amico, J. Falk, C. Glazer, G. Criner

“…We used prospective data from the INBUILD trial to investigate risk factors for acute exacerbations and the impact of these events in patients with progressive pulmonary fibrosis. …”
Get full text

Enhanced Interleukin 6 Trans-Signaling Modulates Disease Process in Amyotrophic Lateral Sclerosis Mouse Models by Carol Milligan, Dale O. Cowley, William Stewart, Alyson M. Curry, Elizabeth Forbes, Brian Rector, Annette Hastie, Liang Liu, Gregory A. Hawkins

“…Intense research efforts have provided insight into unique neuroanatomical regions, specific neuronal populations and genetic associations for ALS and other neurodegenerative diseases; however, the experimental results also suggest a convergence of these events to common toxic pathways. We propose that common toxic pathways can be therapeutically targeted, and this intervention will be effective in slowing progression and improving patient quality of life. …”
Get full text

Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy: a phase Ib study by Ying Fan, Qingyuan Zhang, Min Yan, Xiujuan Qu, Yongmei Yin, Tao Sun, Jin Yang, Ying Wang, Xu Wang, Zhaofeng Niu, Xinshuai Wang, Sanyuan Sun, Weihong Zhao, Yanping Liu, Miao Niu, Xuemin Zhao, Binghe Xu

“…The primary endpoints were maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), and treatment emergent adverse events (TEAEs). The secondary endpoints were pharmacokinetic profiles and efficacy including objective response rate (ORR) and disease control rate (DCR) (all patients) and Central Nervous System ORR and clinical benefit rate (CBR, for patients with HER2-negative BCBM), duration of response, progression free survival (PFS), overall survival (OS). …”
Get full text

Exoskeleton Training for Spinal Cord Injury Neuropathic Pain (ExSCIP): Protocol for a Phase 2 Feasibility Randomised Trial [version 1; peer review: 1 approved, 2 approved with rese... by Orlaith Doherty, Conor White, Nanna Brix Finnerup, Eimear Smith, Mark Pollock, Nathan Kirwan, Olive Lennon, Catherine Blake

“…The primary outcomes are feasibility outcomes for progression to definitive trial which include recruitment and retention rates, adverse events and acceptability of the intervention. Secondary outcomes explore changes in NP intensity and interference as measured by the International Spinal Cord Injury Pain Basic Data Set 3.0 (ISCIPBDS) at baseline, post-intervention (week 13) and at 6-month follow-up. …”
Get full text